Estradiol is a form of estrogen, a female sex hormone that regulates many processes in the body.

Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.

Estradiol and norethindrone transdermal (skin patch) is a combination medicine used to treat menopause symptoms such as hot flashes and vaginal changes (itching, burning, dryness). This medicine is also used before menopause to treat a lack of estrogen caused by conditions such as hypogonadism, primary ovarian failure, or surgical removal of the ovaries.

Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Average rating:  
 0 reviews
  • Combipatch
  • Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

    Call your doctor at once if you have:

    confusion, depression, unusual thoughts or behavior;
    unusual or heavy vaginal bleeding;
    a lump in your breast;
    heart attack symptoms--chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating;
    signs of a stroke--sudden numbness or weakness (especially on one side of the body), sudden severe headache, slurred speech, problems with vision or balance;
    signs of a blood clot in the lung--chest pain, sudden cough, wheezing, rapid breathing, coughing up blood;
    signs of a blood clot in your leg--pain, swelling, warmth, or redness in one or both legs; or
    liver problems--nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
    Common side effects may include:

    nausea, vomiting, bloating, stomach cramps;
    light vaginal bleeding or spotting;
    vaginal itching or discharge;
    headache;
    breast pain; or
    redness or irritation where the patch is worn.
  • Combination estrogen plus progestin regimens are indicated for women with an intact uterus. Two CombiPatch (estradiol/NETA) transdermal delivery systems are available: 0.05 mg estradiol with 0.14 mg NETA per day (9 cm2) and 0.05 mg estradiol with 0.25 mg NETA per day (16 cm2). The lowest effective dose should be used. For all regimens, women should be reevaluated at 3- to 6-month intervals to determine if changes in hormone therapy or if continued hormone therapy is appropriate. Continuous Combined Regimen CombiPatch 0.05 mg estradiol/0.14 mg NETA per day (9 cm2) matrix transdermal system is used for continuous uninterrupted treatment applied twice weekly on the lower abdomen. A new system should be applied to the skin every 3 to 4 days (twice weekly) during a 28-day cycle. Additionally, a dose of 0.05 mg estradiol/0.25 mg NETA (16 cm2 system) is available if a greater progestin dose is desired. Irregular bleeding may occur particularly in the first six months, but generally decreases with time, and often to an amenorrheic state. Continuous Sequential Regimen CombiPatch can be applied as a sequential regimen in combination with an estradiol-only transdermal delivery system. In this treatment regimen, a 0.05 mg per day (nominal delivery rate) estradiol transdermal system (Vivelle-Dot®) is worn for the first 14 days of a 28-day cycle, replacing the system every 3 to 4 days (twice weekly) according to product directions. For the remaining 14 days of the 28-day cycle, CombiPatch 0.05 mg estradiol/0.14 mg NETA per day (9 cm2) transdermal system should be worn continuously on the lower abdomen. The CombiPatch system should be replaced every 3 to 4 days (twice weekly) during this 14-day period in the 28-day cycle. Additionally, a dose of 0.05 mg estradiol/0.25 mg NETA (16 cm2 system) is available if a greater progestin dose is desired. Women should be advised that monthly withdrawal bleeding often occurs.